RecruitingPhase 2NCT06209736
Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN
Studying C3 glomerulonephritis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Omeros Corporation
- Principal Investigator
- Steve Whitaker, MDOmeros Corporation
- Intervention
- OMS906 study drug(drug)
- Enrollment
- 20 enrolled
- Eligibility
- 18-99 years · All sexes
- Timeline
- 2024 – 2026
Study locations (6)
- Omeros Investigational Site, Kaunas, Lithuania
- Omeros Investigational Site, Vilnius, Lithuania
- Omeros Investigational Site, Auckland, New Zealand
- Omeros Investigational Site, Lodz, Poland
- Omeros Investigational Site, Leicester, United Kingdom
- Omeros Investigational Site, Newcastle upon Tyne, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06209736 on ClinicalTrials.govOther trials for C3 glomerulonephritis
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE3NCT05809531An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative GlomerulonephritisApellis Pharmaceuticals, Inc.
- RECRUITINGPHASE2NCT04183101Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 GlomerulopathyRegion Skane
- RECRUITINGPHASE3NCT03955445Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGNNovartis Pharmaceuticals